Prevalence and Clinical Implications of Somatic and Germline EGFR Mutations in Patients with Non-Small-Cell Lung Cancer
Cancers · 27.07.2026 · 18 (15) · 2417
DOI: 10.3390/cancers18152417 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.07.2026. Verfasst von Jingyao Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Danbury Hospital, Zucker School of Medicine at Hofstra/Northwell, Danbury, CT 06810, USA. Die Arbeit nennt 183 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, United States Department of Veterans Affairs, VA Merit Award.
Abstract (Originalsprache)
Epidermal growth factor receptor (EGFR)-targeted therapy represents one of the earliest and most established examples of precision oncology in non-small-cell lung cancer (NSCLC), with more than 10 approved agents, including tyrosine kinase inhibitors, bispecific antibodies and antibody–drug conjugates. Over the past two decades, the diagnostic and therapeutic landscape of EGFR-mutant NSCLC has evolved from empiric treatment to mutation subtype-guided strategies, from advanced disease to earlier-stage interventions, and from monotherapy to rational combination regimens. Somatic EGFR mutations remain key predictive biomarkers guiding treatment selection, therapeutic intensification, resistance mechanism-directed treatment, and disease monitoring through plasma circulating tumor DNA burden. In parallel, germline EGFR alterations are increasingly recognized as contributors to inherited lung cancer susceptibility, particularly among never-smokers and familial clusters. Germline EGFR T790M is the best-characterized pathogenic variant, creating a permissive background for multifocal lung nodules and lung adenocarcinoma development, often following acquisition of a second somatic EGFR driver mutation. Recent familial, regional, and paired tumor–normal sequencing studies have expanded the evidence beyond isolated case reports and support an emerging hereditary lung cancer predisposition phenotype. Clinically, germline EGFR should be suspected when EGFR T790M is detected prior to TKI exposure, particularly at variant allele fractions near 50%, or in patients with multifocal ground-glass nodules, multiple primary lung adenocarcinomas, early-onset disease, never/light smoking history, or family history of lung cancer. Confirmation requires germline testing and genetic counseling. This review highlights the current knowledge, recent advances, and future directions in somatic and germline EGFR-mutant NSCLC, emphasizing translational relevance for clinicians and researchers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Danbury Hospital, Zucker School of Medicine at Hofstra/Northwell, Danbury, CT 06810, USA.
- Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA 95817, USA.
- Medical Service, Hematology/Oncology, Veterans Affairs Northern California Health Care System, Mather, CA 95655, USA.
ORCID-Profile: Jingyao Zhang, Tianhong Li
Förderung
- BLRD VA
- United States Department of Veterans Affairs
- VA Merit Award
- VA-Lung Precision Oncology Program
- California Lung Cancer Coalition
Zitieren
APA
Zhang, J., Zha, L., Liang, R., & Li, T. (2026). Prevalence and Clinical Implications of Somatic and Germline EGFR Mutations in Patients with Non-Small-Cell Lung Cancer. Cancers, 18(15), 2417. https://doi.org/10.3390/cancers18152417
Vancouver
Zhang J, Zha L, Liang R, Li T. Prevalence and Clinical Implications of Somatic and Germline EGFR Mutations in Patients with Non-Small-Cell Lung Cancer. Cancers. 2026;18(15):2417. doi:10.3390/cancers18152417
BibTeX
@article{Zhang2026,
author = {Zhang, Jingyao and Zha, Linjun and Liang, Ruqiang and Li, Tianhong},
title = {Prevalence and Clinical Implications of Somatic and Germline EGFR Mutations in Patients with Non-Small-Cell Lung Cancer},
journal = {Cancers},
year = {2026},
volume = {18},
number = {15},
pages = {2417},
doi = {10.3390/cancers18152417}
}
EUVIMED